Literature DB >> 3116371

Human macrophage-activating factors for cytotoxicity. I. Establishment of a human T-cell hybridoma that produces macrophage-activating factors for cytotoxicity.

M Higuchi1, M Sugimoto, Y Kobayashi, T Osawa.   

Abstract

Human T cell hybridoma, H3-E9-6, that produces macrophage activating factors for cytotoxicity (MAF-C) was prepared by somatic fusion of phytohemagglutinin-activated peripheral blood lymphocytes with emetine/actinomycin D-treated cloned human acute lymphocytic leukemia cells (CEM 11). The activities of the following were assayed: (1) macrophage-activating factor for cytotoxicity of monocytes (MAF-C 1 day), (2) macrophage-activating factor for cytotoxicity of monocyte-derived macrophages (MAF-C 6 day), (3) macrophage-activating factor for cytotoxicity of murine macrophages (MAF-Cm), (4) macrophage-activating factor for glucose consumption (MAF-G), (5) macrophage-activating factor for O2- formation (MAF-O). The culture supernatant of H3-E9-6 showed MAF-C 1 day-MAF-C 6 day, MAF-Cm, and MAF-G activities. The MAF-Cm activity was considerably enhanced by the addition of murine recombinant interferon gamma (rIFN-gamma). The MAF-C 1 day activity in the H3-E9-6 sup was not decreased by heat treatment (56 C, 30 min), by pH 2 treatment or by the addition of monoclonal anti-human IFN-gamma antibody or polymyxin B. These data suggest that MAF-C in H3-E9-6 sup is distinct from human IFN-gamma or lipopolysaccharide (LPS).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116371     DOI: 10.1111/j.1348-0421.1987.tb03109.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

1.  A human macrophage hybridoma producing a cytotoxic factor distinct from TNF, LT, and IL-1.

Authors:  O Shimoda; Y Takeda; H J Woo; S Shimada; M Higuchi; T Osawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.

Authors:  R LaPushin; K Totpal; M Higuchi; B B Aggarwal
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

3.  Anti-tumour efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cells.

Authors:  T Okada; M Higuchi; M Takano; T Maruyama; Y Imai; T Osawa
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

Review 4.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

5.  Tumor-specific T cells which form clusters with dendritic cells and tumor cells and deliver macrophage-activating factors.

Authors:  Y Yamaguchi; K Inaba; J Kawai; T Kato; S Nakamura; K Uno; S Muramatsu
Journal:  Jpn J Cancer Res       Date:  1989-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.